Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

90.24USD
3:59pm EST
Change (% chg)

$0.37 (+0.41%)
Prev Close
$89.87
Open
$90.24
Day's High
$90.45
Day's Low
$89.50
Volume
487,196
Avg. Vol
427,360
52-wk High
$102.43
52-wk Low
$72.99

BMRN.OQ

Chart for BMRN.OQ

About

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha),... (more)

Overall

Beta: 1.60
Market Cap(Mil.): $15,456.51
Shares Outstanding(Mil.): 171.99
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 28.39 29.32
EPS (TTM): -2.96 -- --
ROI: -14.42 13.54 13.03
ROE: -19.56 14.43 14.17

BRIEF-Jennison Associates Llc reports 5.4 pct passive stake in Biomarin Pharmaceutical

* Jennison Associates Llc reports 5.4 percent passive stake in Biomarin Pharmaceutical Inc as of Dec 31, 2016- sec filing Source text - http://bit.ly/2jIyNQd Further company coverage:

Feb 02 2017

BioMarin Pharma cites positive results for hemophilia treatment

Jan 8 BioMarin Pharmaceutical Inc announced on Sunday what it called "positive interim results" from its study of a gene therapy treatment for severe hemophilia.

Jan 08 2017

BRIEF-BioMarin announces Q3 GAAP loss per share of $0.26

* Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S

Oct 27 2016

BRIEF-Biomarin Pharmaceutical provided update on mod-stage study of vosoritide

* Biomarin Pharmaceutical - Provided update on phase 2 study of vosoritide, analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia

Oct 19 2016

BRIEF-UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study

* UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study of BMN 270 in Hemophilia a

Oct 13 2016

BRIEF-BioMarin reviews status of Exon 51 composition of matter

* To seek review of patent trial and appeal board ruling, for composition of matter claims related to exon 51 skipping antisense oligonucleotides

Sep 21 2016

BRIEF-BioMarin announces update to Brineura program

* BioMarin announces update to Brineura (cerliponase alfa) program for treatment of CLN2 disease, a form of batten disease

Sep 06 2016

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $119.66 +0.80
Pfizer Inc. (PFE.N) $33.62 0.00
Novartis AG (NOVN.S) CHF77.40 +0.70
Merck & Co., Inc. (MRK.N) $65.48 +0.09
Roche Holding Ltd. (ROG.S) CHF246.50 +2.50
Roche Holding Ltd. (RO.S) CHF249.60 +1.80
Abbott Laboratories (ABT.N) $45.01 +0.32
Bayer AG (BAYGn.DE) €108.90 +1.70
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €80.53 -0.02

Earnings vs. Estimates